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The International Myeloma Working
Group consensus updates the definition
for high-risk (HR)multiplemyelomabased
on cytogenetics Several cytogenetic ab-
normalities such as t(4;14), del(17/17p),
t(14;16), t(14;20), nonhyperdiploidy, and
gain(1q) were identified that confer poor
prognosis. The prognosis of patients
showing these abnormalities may vary
with the choice of therapy. Treatment
strategies have shown promise for HR
cytogenetic diseases, such as proteasome
inhibition incombinationwith lenalidomide/
pomalidomide,doubleautologousstemcell
transplant plus bortezomib, or combination
of immunotherapy with lenalidomide or
pomalidomide. Careful analysis of cytoge-
netic subgroups in trials comparing differ-
ent treatments remains an important goal.
Cross-trial comparisons may provide in-
sight into the effect of newdrugs in patients
withcytogeneticabnormalities.However, to
achieve this, consensus on definitions of
analytical techniques, proportion of abnor-
mal cells, and treatment regimens is
needed. Based on data available today,
bortezomib and carfilzomib treatment
appear to improve complete response,
progression-free survival, and overall sur-
vival in t(4;14) and del(17/17p), whereas
lenalidomide may be associated with
improved progression-free survival in
t(4;14) and del(17/17p). Patients with
multiple adverse cytogenetic abnormali-
tiesdonot benefit from theseagents. FISH
data are implemented in the revised In-
ternational Staging System for risk strat-
ification. (Blood. 2016;127(24):2955-2962)
Introduction
Multiplemyeloma (MM) is a proliferation ofmonoclonal plasma cells
that produce amonoclonal protein.1 Indications for treatment are based
onend-organdamage (hypercalcemia, renal impairment, anemia, bone
lesions) and markers of active disease (ie, an involved:uninvolved
serum-free light-chain ratio$100, bone marrow plasma cells$60%,
or.1 lesion found on magnetic resonance imaging).2
Response to treatment and survival of newly diagnosed MM
(NDMM) is heterogeneous, with median overall survival (OS) ranging
from 2 to.10 years. MM is characterized by chromosomal instability,
and cytogenetic abnormalities (CA) have an impact on prognosis.1-4
This perspective will deﬁne high-risk (HR) CA and provide recom-
mendations for treatment of HR NDMM patients.
Methods
We will describe techniques for identiﬁcation of CA followed by a discussion
of prognostic impact and treatments. This perspective was developed by an
international expert panel based on evidence of published studies through
November 15, 2015. The statement was drafted and circulated among all panel
members, followed by rounds of revision.
Diagnostic techniques for CA
Conventional karyotyping. Karyotyping reveals CA in 20% to 30% of
patients, those being mainly numerical abnormalities. Several transloca-
tions including t(4;14) are not detected. The normal karyotype in patients
with a low proliferation index corresponds to the kinetics of normal bone
marrow cells. Abnormal karyotype had an unfavorable impact in the Total
Therapy programs.5 Because more sensitive techniques reveal CA in nearly
all MM, karyotyping is not a routine test.
Fluorescence in situ hybridization. Fluorescence in situ hybridiza-
tion (FISH) is performed in interphase cells, thereby overcoming the
problem of karyotyping. Puriﬁcation of CD138-expressing plasma cells or
dual staining for cytoplasmic immunoglobulin (Ig) and FISH are required
for FISH. Currently, FISH is the standard technique for analysis of CA.
Samples are usually screened for CA,which occur in.1%of patients. FISH
is a practical cytogenetic tool to detect genomic aberration in situ and to
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enumerate the percentage of cells harboring such abnormalities. It does not
detect single-nucleotide variants.6 For example, TP53 on chromosome 17p
is deleted in 7% of myeloma, yet mutated at a much higher frequency in
myeloma based on exome sequencing. Knowing these restrictions, FISH
testing may include gain(1q), del(1p), t(4;14)(p16;q32), t(14;16(q32;q23),
del(17p13), and a marker for aneuploidy (Table 1). For routine diagnosis,
testing of t(4;14) and del(17p13) sufﬁces.
Singe-nucleotide polymorphism–based mapping arrays. High-resolution
genome-wide analysis (GWAS) of single-nucleotide polymorphisms (SNP)
detects regions with loss of heterozygosity and numerical abnormalities. SNP
mapping arrays identify copy number variations (CNV). Translocations are not
usually detected and will require additional FISH.
Comparative genomic hybridization. Array-based comparative geno-
mic hybridization is a tool for genome-wide classiﬁcation of CNVs, which
primarily detects numerical abnormalities.
Gene expression proﬁling. Gene expression proﬁling (GEP) is a
technique to identify expression of genes and pathways. Based on RNA
expression using microarrays, subgroups of patients are identiﬁed with a unique
GEP phenotype that partly corresponds to the TC classiﬁcation.7 GEP from
patients in clinical trials can be used to identify HR proﬁles with signiﬁcant
prognostic signiﬁcance.8
Consensus statement. FISH is the standard approach for identiﬁcation of
primary genetic events and secondary numerical events. SNP-based mapping
arrays and CGH are more sensitive techniques to detect small numerical
aberrations, and therefore these can be used in clinical trials. GEP proﬁling is
useful for prognostication and may require bioinformatics support.
High-risk CA
IgH translocations. In MM, primary events are chromosome translocations
involving the immunoglobulin heavy chain (IgH) locus and hyperdiploidy, with
multiple copies of odd-numbered chromosomes (Table 1).9 IgH translocations
are observed in 40% of cases. Frequently involved partner chromosomes/loci
are 4p16 (FGFR3/MMSET) (12%-15%), 11q13 (CCND1) (15%-20%), 16q23
(MAF) (3%), 6p21 (CCND3) (,5%), and 20q11 (MAFB) (1%).10
Translocation t(4;14) leads to deregulation of ﬁbroblast growth factor
receptor 3 (FGFR3) andmultiplemyeloma SET domain (MMSET).11,12 Because
FGFR3 is not expressed in one third of patients with t(4;14), the target gene is
most likely MMSET.13 t(4;14) is associated with impaired progression-free
survival/overall survival (PFS/OS).14 Importantly, bortezomib seems to improve
thenegative prognostic impact of t(4;14).15-18 Prolonged survivalwas reported in
t(4;14) treated with high-dose therapy (HDT) and tandem autologous stem cell
transplant (ASCT).19,20 SNP arrays showed the heterogeneous adverse impact of
t(4;14) related to concomitant CA.21
Translocation t(14;16) results in deregulation of the c-MAF proto-oncogene
and predicts poor outcome.11,12,22 An Intergroupe Francophone de Myelome
(IFM) analysis showed no adverse impact of t(14;16), possibly because 60% of
patients receivedadoubleASCT.23Translocation t(14;20) results inderegulation
of theMAFB oncogene and confers a poor prognosis.12
Translocation t(11;14) results in upregulation of cyclinD1 andwas identiﬁed
as favorable in some studies, whereas it had no impact in others.14,24,25 This
translocation is associated with CD20 expression and a lymphoplasmocytic
morphology. In general t(6;14), t(11;14), gain(5q), and hyperdiploidy do not
confer poor prognosis.
Genomic imbalance. Hyperdiploidy,which occurs in;50%ofNDMM,
is associated with improved PFS/OS.11,25 In the MRC IX trial, coexisting
hyperdiploidy did not abrogate the poor prognosis of adverse CA.26 In contrast,
in a retrospective analysis, PFS of patients with t(4;14) was negatively affected
by del(1p32), del22q, and .30 structural CA, whereas del(6q) worsened PFS
and del(1p32) worsened OS, and .8 numerical changes improved OS in del
(17p).21Modern techniques (GWAS) identify additional CNVabove karyotypic
hyperdiploidy.27
Del(13q) predicts impaired PFS/OS when detected by karyotyping.28 The
adverse impact of del(13q) by FISH is associated with del(17p) and t(4;14). del
(13q) as single CA does not confer poor survival.11,12,25,29
Del(17p) or del(17) has a negative impact on PFS/OS. Deletion of TP53
induces clonal immortalization and survival of tumor cells.30
Patients with$3 copies of 1q have a worse treatment outcome, reﬂecting a
dosage effect of genes such asCKS1B.12,29,31Gain(1q) frequently coincideswith
del(1p32), which confers poor prognosis.21,32-34 Hypoploidy is regarded as a
poor prognostic CA.
It is currently unclear which minimum percentage of cells carrying del(17p)
is required for an adverse prognosis or whether this varies with the choice of
therapy and stage of disease. Minimal percentages of 20% and 60% have been
recommended for del(17p).12,21An international effortwill address this issue in a
meta-analysis.
The prognostic impact ofCAmayvary fromdiagnosis to (refractory) disease
because of the selection of subclonal disease.35 In solitary plasmacytoma or
extramedullary disease, del(17p) may occur more frequently.36,37
Multiple adverse CA. Among patients with an adverse IgH trans-
location 62% have gain(1q) compared with 32.4% in controls.12
The frequency of del(17p) is similar in patients without adverse IgH
translocations. Among patients with an IgH translocation and/or gain1q or
del(17p), 20% shared$2 CA. When CA occurred in isolation, each lesion
had a similar impact on OS. The triple combination of an adverse IGH
translocation, gain(1q), and del(17p) was associated with a median OS of
9.1 months,12 demonstrating the progressive impact of cosegregation of
multiple adverseCAonOS. The IFM showed that in 110 patients displaying
either t(4;14) or del(17p), 25 had both abnormalities. In patients with
t(4;14), PFS was worse with concomitant del(1p32), del(22q), and/or .30
structural changes, whereas del(13q14), del(1p32), and higher number of
CA shortened OS. In patients with del(17p), del(6q)reduced PFS, whereas
gain15 and del14 had a protective effect. Del(1p32) shortened OS, whereas
.8 numerical changes improved OS.21
Good combined with adverse CA. Gain of 5(q31) improved outcome
with hyperdiploidMM.38 Among patients with hyperdiploidy, trisomies 3 and 5
confer a favorable prognosis.21
Table 1. Primary and secondary genetic events that can be identified by FISH
Primary genetic events Secondary genetic events
IgH translocation Gene(s) Frequency (%) Deletion Gene(s) Frequency (%)
t(4;14) FGFR3/MMSET 15 1p CDKN2C, FAF1, FAM46C 30
t(6;14) CCND3 4 6q 33
t(11;14) CCND1 20 8p 25
t(14;16) MAF 4 13 RB1, DIS3 44
t(14;20) MAFB 1 11q BIRC2/BIRC3 7
14q TRAF3 38
16q WWOX, CYLD 35
17p TP53 7
Hyperdiploidy Gain
Trisomies of chromosomes 3,
5, 7, 9, 11, 15, 19, 21
NA 50 1q CKS1B, ANP32E 40
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In the Myeloma IX study, 58% of patients had hyperdiploidy.39 Of these,
61% had$1 adverse lesion (t(4;14), t(14;16), t(14;20), gain1q, or del(17p). OS
and PFS were worse in patients with hyperdiploidy plus an adverse lesion,
compared with hyperdiploidy alone (median PFS, 23 vs 15.4 months; median
OS, 60.9 vs 35.7 months). Alternatively, presence of hyperdiploidy did not
change the outcome in patients with an adverse lesion.
Presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or TP53
deletion in MM reduced their adverse impact.40
Cytogenetic risk classifications
The deﬁnition of HR disease is subject to diagnostic and treatment options. With
median PFS andOS of transplant-eligible (TE) patients approaching 4 and 10 years,
most investigators consider HR disease as OS ,3 years, with ultra-HR disease
havingasurvival,2years.Fornon–transplant-eligiblepatients (NTE)OS,,2years
is consideredHR.41,42 It is important todeﬁneHRdisease basedonobjective criteria.
Risk classiﬁcations based on FISH. IMWG proposed a model of HR
MM deﬁned as at least one of the following: del17p, t(4;14), or t(14;16)
determined by FISH.43 The Mayo Clinic classiﬁcation added hypodiploidy
and t(14;20) to the deﬁnition of HR MM (Table 2).44 Later classiﬁcations
attempted to separate MM into several risk groups. In MRC IX, 3 groups
were identiﬁed (ie, favorable risk [FR: no adverse IgH translocation, del
(17p), or gain(1q]), intermediate risk (IR: 1 adverse CA), and HR (.1
adverse CA).Median PFS/OS of patients with FR, IR, or HRwas 23.5, 17.8,
and 11.7 months and 60.6, 41.9, and 21.7 months, respectively.12 Ultra-HR
was deﬁned as $3 CA (2%; median OS, 9 months). These classiﬁcations
may changewith treatmentmodalities. An example is t(4;14), whichmay be
IR rather than HR when novel agents are given.15,45,46 IMWG stated that
HR MM should include t(4;14), t(14;16), or del(17p).47
Risk classiﬁcations based on FISH and ISS. The combination of
International Staging System (ISS) with HR CA reﬂects tumor mass, patient
condition, and genetics. IMWG showed that t(4;14) and/or del(17p) separates
Table 2. Summary of cytogenetic risk features
High-risk Standard-risk
Cytogenetic abnormality FISH: t(4;14), t(14;16), t(14;20), del(17/17p),
gain(1q)




Table 3. Survival of MM patients with high-risk FISH compared with those without high-risk FISH
FISH Np/Na End point Therapy Present Absent Comment Ref
Conventional therapy
t(4;14) 42/290 3-y OS VBMCP 24% 64% E9486 13
100/616 3-y OS VAD 1 ASCT 3 2 55% 80% IFM-99 25
98/414 3-y OS VAD 1 ASCT 3 1/2 40% 72% IFM-2005 68
del17p 37/308 3-y OS VBMCP 32% 68% E9486 13
58/474 3-y OS VAD 1 ASCT 3 2 50% 78% IFM-99 25
119/393 3-y OS VAD 1 ASCT 3 1 49% 82% IFM-2005 68
Unfavorable FISH 141/166 3-y OS CVAD 1 ASCT 3 1 58% 81% MRC IX intensive 62
90/125 3-y OS MP 26% 48% MRC IX non-intensive 61
98/129 3-y OS Placebo maintenance 69% 72% MRC IX maintenance 39
18/111 3-y OS VBMCP/VBAD 1Bz 3 2 1 ASCT 3 1 48% 84% GEM2005 ,65 63
Thalidomide
t(4;14) 57/181 3-y PFS TD 1 ASCT 3 2 1 TD 20% 48% GIMEMA 102
26/156 3-y OS VAD 1 ASCT 3 1 1 Thal maintenance 44% 79% HOVON65/GMMG-HD4 29
del17p 21/161 3-y OS VAD 1 ASCT 3 1 1 Thal maintenance 17% 79% HOVON65/GMMG-HD4 29
Unfavorable FISH 43/302 5-y OS Thal induction, consolidation, maintenance 56% 72% Total Therapy 2 18
152/167 3-y OS CTD 1 ASCT 3 1 59% 82% MRC IX intensive 62
96/129 3-y OS CTDa 58% 78% MRX IX non-intensive 61
99/126 3-y OS Thalidomide maintenance 45% 76% MRX IX maintenance 39
17/110 3-y OS TD 1 ASCT 3 1 56% 86% GEM2005 , 65 63
Lenalidomide
t(4;14) 28/102 Median OS RD in RRMM 18 m 23 m MM-016 103
26/158 Median OS RD in RRMM 9 m 15 m IFM 83
152/355 Median PFS Lenalidomide maintenance 27 m 42 m IFM-2005 68
del17p 12/118 Median OS RD in RRMM 4 m 23 m MM-016 103
6.6% Median PFS Lenalidomide maintenance 29 m 42 m IFM-2005 68
Unfavorable FISH 16/84 3-y OS RD 77% 86% Mayo Clinic 76
21/105 2-y OS RD 76% 91% E4A03 104
Bortezomib
t(4;14) 106/401 4-y OS VD 1 ASCT 3 1 63% 85% IFM-2005 68
53/183 3-y PFS VTD 1 ASCT 3 2 1 BzTD 65% 61% GIMEMA 102
24/148 3-y OS VAD 1 ASCT 3 1 1 Bz 66% 82% HOVON65/GMMG-HD4 29
del17p 54/453 4-y OS VD 1 ASCT 3 1 50% 79% IFM-2005 68
16/158 3-y OS VAD 1 ASCT 3 1 1 Bz 69% 82% HOVON65/GMMG-HD4 29
Unfavorable FISH 18/112 3-y OS VTD 1 ASCT 3 1 60% 88% GEM2005 ,65 63
44/188 3-y OS VMP/BzTP, BzT/BzP 55% 73% GEM2005 ,65 73
28/140 3-y OS VMP 56% 71% VISTA 72
Adapted from Bergsagel et al.58
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2groupswith different event-free survival (EFS) andOSwithin each ISS stage.48
Combining t(4;14) and del(17p) with ISS stage improved prognostic staging.48
Neben et al combined ISS with t(4;14) or del(17p).11 Median PFS after ASCT
were2.7, 2.0, and1.2 years for theFRgroup (ISS I, noHRCA), IR (ISS I andHR
CA or ISS II/III without HRCA), and HR (ISS II/III and HRCA). Five-year OS
were 72%, 62%, and 41%, respectively. Identical results were obtained in the
Hovon-65/GMMG-HD4 trial.29
TheMRC IX study combined ISS and the presence of 0, 1, or.1 adverseCA.
MedianOSin theultra-HRgroup,deﬁnedbyISSIIor IIIplus.1adverseCA,were
9.9 and 19.4 months, compared with OS 67.8 months in the favorable group.12
Risk classiﬁcations based on FISH, ISS, and lactodehydrogenase.
Ameta-analysis of randomized trials in NDMM conﬁrmed that combining ISS,
serum lactodehydrogenase (LDH), and FISH identiﬁes 4 risk groups including
a very HR population (5%-8%). Patients with ISS stage III, elevated LDH, and
t(4;14) or del(17p) have a 2-year OS of only 54.6%.49More recently, the revised
ISS was deﬁned, incorporating HR FISH (t(4;14), t(14;16), and del(17p) with
ISS and LDH.50
Gene expression proﬁling. The prognostic impact ofGEPbymicroarray
was examined in several studies. The UAMS identiﬁed a 70-gene subset as an
independent prognosticator.51 Presence of a HR signature (13.1%) resulted in
inferiorEFS (5-yearEFS: 18%vs60%) andOS (5-yearOS: 28%vs78%). In this
signature, several genesmapped to chromosome1(q) and (1p).20The samegroup
performed GEP analysis 48 hours after bortezomib dosing in TT3.52 Based on
GEP changes, the UAMS-80 signature was constructed.
The EMC-92 signaturewas derived from patients in theHovon-65/GMMG-
HD4 trial. When combined with ISS, it predicts impaired PFS and OS across
treatments.53,54 OS of HR patients (21%) at 5 years was 10% compared with
72% for others (79%). Other GEP-based risk models include the IFM-15 and
MRC IX-6 gene signatures.55 In general, these GEP signatures are useful for
prognostication, whereas prediction has to be validated.56
mSMART. The Mayo Stratiﬁcation of Myeloma and Risk-Adapted
Therapy (mSMART) criteria use a combination of FISH, plasma cell labeling
index, andGEP as tools to identify 3 risk categories (standard risk [SR], IR, HR)
for prognostication of patients with NDMM.57 Patients can be stratiﬁed for
different therapeutic approaches.47 However, risk-adapted therapy has not been
validated in prospective studies.
Consensus statement. Translocations t(4;14), t(14;16), t(14;20), and
del(17/17p) and any nonhyperdiploid karyotype are HR cytogenetics inNDMM
regardless of treatment. Gain(1q) is associated with del(1p) carrying poor risk.
Combinations of$3CAconfer ultra-HRwith,2years survival.Routine testing
should include t(4;14) and del(17p). Clinical classiﬁcations may combine these
lesions with ISS, serum LDH, or HR gene expression signatures. CAmay differ
in ﬁrst and later relapse because of clonal evolution, which may inﬂuence the
effect of salvage treatment.
Treatment options for high-risk disease
IMWGrecommendsusing the combinationofFISH,LDH, and ISS stage for risk
stratiﬁcation in NDMM.47 Other features such as renal failure, plasma cell
proliferative rate, and presence of extramedullary disease also contribute to risk.
GEP is emerging as a prognostic tool for risk stratiﬁcation. New approaches to
predict survival include analysis of microRNAs, custom capture mutation
analysis, and evaluation of methylation and splicing patterns.
Hereweaddress the treatment choices for patientswithHRNDMMbasedon
cytogenetic proﬁle. Recently, 2 reviews addressed the issue of general treatment
strategies for HRmyeloma.58,59 This review covers treatment options for t(4;14)
and/or del(17/17p).
Thalidomide. Thalidomide does not overcome adverse impact ofHRCA.
In the UAMS trial for RRMM, del(13q) by karyotyping had a shorter survival
with thalidomide.60 Three trials studying thalidomide during induction in
NDMM (MRC IX: CTD vs CTDa; HOVON50/GMMG-HD2: VAD vs TAD;
GEM2005:TD) observed shorter OS in HR CA.61-64 Thalidomide maintenance
did not improve survival inHRCA in3 trials,MRCIX (3-yearOS45%vs 69%),
HOVON50 (3-year OS 17% vs 69%) trials and Total Therapy 2 (TT2) (5-year
OS 56% vs 72%).15,18,25,61,62,65 In MRC IX, 3-year OS was worse in patients
with HR-CA (45%).66 In HOVON50/GMMG-HD2, ﬁrst PFS was better with
thalidomide treatment, but second PFS was signiﬁcantly shorter, resulting in a
reducedOS.64 In TT2, presence of CAwas associatedwith inferior survival, and
a beneﬁt with thalidomide was only observed in a subgroup of patients after
10 years.67
Consensus statement. Thalidomide does not abrogate the adverse effect
of t(4;14), t(14;16), t(14;20), and del(17) or del(17p) and gain(1q) CA in TE
patients. Conclusive data for elderly or frail patients are not available.
Bortezomib. Several randomized trials have evaluated bortezomib for
induction, consolidation, or maintenance treatment in cytogenetic subgroups. In
IFM-2005-01, bortezomib/dexamethasone showed a superior response and OS
compared with vincristin/doxorubicin/dexamethasone. This combination
resulted in a better EFS and OS for patients with t(4;14), but did not improve
outcome in del(17p) (4-year OS 50% vs 79%).68 In HOVON65/GMMG-HD4,
bortezomib-based inductionandmaintenance showedan improvedoutcome for
patients with del(17p) (median PFS 26 vs 12months; 3-year OS 69% vs 17%)).
At long-term follow-up, this advantage is still present. However, OS remains
inferior to patients without del(17p) (3-year OS 85%). In patients with t(4;14),
PFS was not better with bortezomib (25 vs 22 months), whereas OS was
improved (3-year OS 69% vs 44%) compared with 85% in patients without
t(4;14).29 In the GEM 2005 trial, bortezomib/thalidomide/dexamethasone
(VTD) followed by ASCT and maintenance did not improve OS in HR
CA (3-year OS 60% vs 88%).63 The GIMEMA group compared VTD with
thalidomide/dexamethasone (TD) for induction and consolidation with double
ASCT. In the subgroup of 25%with t(4;14),OSwas 69%vs 37% in favor ofVTD
comparedwith74%vs63%without t(4;14) and/ordel(17p).17Ameta-analysisof4
randomized trials showed that the odds of posttransplantation complete response
(CR) 1 near CR in bortezomib-treated patients were similar for HR (del(17p) 1
t(4;14)) and SR cytogenetics (2.44 vs 1.67, n.s.).16 These trials (1874 patients)
showed that bortezomib plus ASCT was superior (PFS 41 vs 33 months)
(P, .0001). In patientswithHRFISH, thiswas 32 vs 22months (P, .0001). PFS
beneﬁt was observed in patientswith t(4;14) but lacking del(17p) (36 vs 24months,
P5 .001) and in del(17p) lacking t(4;14) (27 vs 19 months, P5 .014), but not in
patients carrying both CA.69 In TT3, OSwas signiﬁcantly shorter in patients with a
HR proﬁle (2-year OS 56% vs 88%) compared with SR GEP proﬁle, with the
Table 4. Survival of high-risk genetic subgroups in randomized, controlled clinical trials of newly diagnosed MM: effect of treatment
modalities and novel drugs
FISH N1/N2 End point Arm 1 Arm 2 Arm 1 (%) Arm 2 (%) Comment Ref
t(4;14) 26/24 3-y OS PAD/ASCT/thalidomide* VAD/ASCT/bortezomib* 44 66 HOVON65/GMMG- HD4 15
98/106 4-y OS VAD VD 32 63* IFM-2005 68
21/23 2-y OS Thalidomide* Placebo* 67 87 TT2 18
21/29 2-y OS Thalidomide-TT2 Bortezomib TT3 67 97* TT2 vs TT3 70
Del(17p) 21/16 3-y OS VAD/ASCT/thalidomide PAD/ASCT/bortezomib* 17 69* HOVON65/GMMG-HD4 15
119/54 4-y OS VAD V D 36 50 IFM-2005 68
Nonhyperdiploid 92 3-y OS VTD VMP 53 72* PETHEMA 63
Unfavorable FISH 152/141 3-y OS CTD VAD-cyclophosphamide 58 56 MRC IX intensive 62
96/90 3-y OS CTD Placebo MP 34 26 MRC IX nonintensive 61
99/98 3-y OS Thalidomide Placebo 45 69* MRC IX maintenance 39
Adapted from Bergsagel et al.58
*Significant better survival outcome.
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exception of low TP53 expression.70 Addition of bortezomib improved OS
compared with TT2 in LR MM.70,71
Data in NTE patients are scarce. The VISTA trial combined melphalan/
prednisone (MP) with MP1 bortezomib (VMP). In patients treated with VMP,
HR-CAdid not inﬂuence outcomewhen comparedwith SR (OS 56%vs 71%).72
In a Pethema trial comparing VMP with bortezomib/thealidomide/prednisone
(VPT) followed by maintenance with bortezomib/thalidomide vs bortezomib/
prednisone, HR patients had shorter PFS than SR patients from the ﬁrst (24 vs 33
months) and second randomization (17 vs 27months) and shorter survival (3-year
OS: 55% vs 77%).73 The GIMEMA group compared VMP with VMP/
thalidomide. In this bortezomib-dense treatment, HR vs SR patients had similar
PFS.74 The IFM group observed that across bortezomib regimens, no beneﬁt was
achieved in HR-CA NTE patients.75
Consensus statement. Bortezomib partly overcomes the adverse effect of
t(4;14) and possibly del(17p) on CR, PFS, and OS. There is no effect in t(4;14)
combined with del(17p) in TE patients. In non-TE patients, VMP may partly
restore PFS in HR cytogenetics.
Lenalidomide and pomalidomide. Experience with lenalidomide in
first-line therapy for HR-CA patients is limited. In HR-CA, PFS with
lenalidomidewas inferior comparedwith SRpatients (18 vs 26months).76 In the
GIMEMA trial comparing high-dose melphalan with MPR, there was a trend
for better PFS with lenalidomide maintenance in SR compared with HR-CA
(HR0.38 [0.24-0.62] vs0.73 [0.37-1.42]).However, therewasnoeffect onOS.77
In the IFM 2005-02 trial, lenalidomide maintenance did not overcome the
poor prognosis of t(4;14) (27 vs 24 months) and only partly of del(17p) (29 vs
14 months vs 42 months in all patients).78 Convincing data for continuous
lenalidomide inCAgroups are lacking.79,80 Subgroup analysis of the FIRST trial
inNDMMdidnot demonstrate a beneﬁt of continuous lenalidomide inHRCA.81
In relapse MM, carﬁlzomib combined with lenalidomide and dexamethasone
(K-RD) was effective across HR and SR patients (23 vs 29 months, P 5 NS),
whereasRDshowed less activity (13 vs 19months,P5 .004).82Data of IFMdid
not show a beneﬁt of RD in relapse/refractory multiple myeloma (RRMM)with
del(13q) or t(4;14).83 In the Eloquent 2 trial for RRMM, elotuzumabwith RD
(E-RD) improved outcome over RD in del(17p).84 Recent data of the effect of
pomalidomide with dexamethasone in patients with RRMM show that this
combinationdoesnot abrogate overall adverse outcome inHR-CA,whereasOS
may improve in del(17p).85 Inphase2 trials, a responsebeneﬁt of pomalidomide
with dexamethasone was shown in patients with del(17p).86
Consensus statement. Lenalidomide partly improves the adverse effect
of t(4;14) and del(17p) on PFS, but not OS, in TE patients. In non-TE patients,
there are no data suggesting that the drug may improve outcome with HR
cytogenetics. Pomalidomide with dexamethasone showed promising results in
RRMM with del(17p).
Combined proteasome inhibition and lenalidomide. Bortezomib
combined with RD (VRD) in a phase 1/2 trial in 66 patients with NDMM
showed18-monthPFSof 100%in13patientswithdel(17p) and/or t(4;14).87The
EVOLUTION trial examined several schedules including VRD in NDMM.
One-year PFS was similar in HR-CA (17% of all patients) and SR patients.88
VRD in TE patients with NDMMhad similar 3-year PFS (86%) in patients with
.60% del(17p) or t(4;14) or del(13q) compared with all patients.89
Carﬁlzomib monotherapy did not improve PFS/OS in t(4;14) or del(17p)
in RRMM.90 Carﬁlzomib combined with pomalidomide/dexamethasone had
equivalent PFS and OS in HR vs SR RRMM.91 In the Aspire trial, in RRMM,
KRDwas superior to RD for PFS across cytogenetic risk groups, suggesting that
this combination (partly) abrogates the negative impact of t(4;14) and del(17p).82
Similarly, in Tourmaline-MM1, ixazomib combined with RD showed identical
PFS in patients with del(17p) or t(4;14) or no CA (20 vs 18 vs 20 m).92 More
recently, carﬁlzomib combined with lenalidomide (KRd) or thalidomide (KTd)
and dexamethasone in NDMM showed similar CR rate (.60%) and PFS
between HR and SR patients.93,94
Recently, favorable responses were observed with monoclonal antibodies
against CD38 (daratumumab) or SLAMF7 (elotuzumab) combined with RD in
RRMM across cytogenetic subgroups.95
Consensus statement. Combining a proteasome inhibitor with lenalido-
mide and dexamethasone greatly reduces the adverse effect of t(4;14) and
del(17p) on PFS in NDMM.Carﬁlzomibwith lenalidomide and dexamethasone
seems effective in patients with HR cytogenetics. However, with exception
of Aspire and Tourmaline, most data were obtained in nonrandomized studies
and long-term follow-up has not been reported. The group advises treating
NDMM patients with HR cytogenetics with the combination of a proteasome
inhibitor with lenalidomide or pomalidomide and dexamethasone.
High-dose therapy and ASCT. In TE patients with NDMM, the
hallmark of ﬁrst-line treatment is high-dose therapy and ASCT combined with
novel agents. This strategy has signiﬁcantly improved PFS andOS. Therefore, it
is difﬁcult to address the role of HDT/ASCT for HR-CA. Few studies have
investigated the effect of a second ASCT. In TT3, the addition of bortezomib to
double ASCT improved outcome in patients with t(4;14), indicating that the
effect of HDT/ASCT varies with induction and consolidation/maintenance.5
Similarly, addition of RVD for consolidation and maintenance after ASCTmay
improve PFS in HRMM.96,97 A meta-analysis of 4 European trials showed that
double ASCT combined with bortezomib-based treatment partially abrogates
poor PFS in patients carrying both t(4;14) and del(17p).69
Consensus statement. HDT with ASCT is standard therapy for TE
patients with NDMM. It contributes to improved outcome across prognostic
groups. Double HDT/ASCT combined with bortezomib may improve PFS in
patients with t(4;14) or del(17p), and in those with both abnormalities. Although
results from stratiﬁed randomized trials are not yet available, HDT plus double
ASCT is recommended for patients with HR cytogenetics. The results from
clinical trials with bortezomib and thalidomide combinations with/without
HDT1ASCT in HR cytogenetics are summarized in Tables 3 and 4.
Allogeneic stem cell transplantation. Allogeneic SCT has been
proposed as a treatment of HR younger patients. Data on CA are scarce and
partlybasedonclassickaryotyping. In a trial of 73NDMMpatients, tandemauto-
allo-transplantation yielded similar 5-year PFS (24% vs 30%) and OS (50% vs
54%) in patients without t(4;14) or del(17p).98 The EBMT-NMAM2000 study
showed better OS in patients treated with ASCT/RIC-allo or ASCT alone: 49%
vs 36% at 96 months, respectively (P5 .030) Unfortunately, convincing FISH
data are lacking.99 A retrospective analysis in 143 patients indicated that patients
with del(13q) or t(4;14) or del(17p) or t(11;14) had similar 3-year PFS and OS
as patients without abnormality.100 A study of allo-SCT in 101 relapsed MM
showedworse4-yearPFS (28vs43%)andOS(30vs49%) in16patientswithdel
(17p), whereas in 16 patients with t(4;14) no impact was observed.101
Consensus statement. Allogeneic SCT or tandem auto-allo-SCT may
improve PFS in patients with t(4;14) or del(17p). Results are better in an early
stage of the disease. The novel treatmentsmay challenge the role of allo-SCTand
its use should be restricted to clinical trials.
Concluding remarks and future perspectives
Risk stratiﬁcation in MM is important to predict survival and to deﬁne
a treatment strategy. Cytogenetic abnormalities by FISH currently are
clinically relevant prognostic factors in MM. The IMWG consensus
panel on FISH advises to test for the presence of del(17p), t(4;14), and
possibly t(14;16). An extended panel, which may be incorporated in
clinical trials, includes t(11;14), t(14;20), gain(1q), del(1p), del(13q),
and ploidy status. Bortezomib and lenalidomidemay partially abrogate
the adverse effect of del(17p). Bortezomib combined with iMIDSmay
improve outcome in t(4;14). Double HDT/ASCT plus bortezomibmay
improve outcome in patients with both adverse CA. Application of
these risk factors may be a ﬁrst step toward precision medicine in
patients with MM.
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